New Biotech SynDevRx, Inc. Establishes Scientific Advisory Board with Key Anti-Angiogenesis and Oncology Leaders
1/8/2008 8:29:07 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SynDevRx™, Inc., a pre-clinical stage biotech company developing the potent anti-angiogenic compound Caplostatin™, announced today the formation of its Scientific Advisory Board. Chairing the SAB is Bruce R. Zetter Ph.D., Chief Scientific Officer of Children’s Hospital Boston and VP Research Harvard Medical School. Dr. Zetter brings a wealth of industry knowledge to SynDevRx.
comments powered by